In Gastroesophageal reflux disease (Acid reflux) Gastroesophageal reflux disease (GERD) is a chronic (long-term) condition in which there is an excess production of acid in the stomach. Syspride Mps 125mg/10mg Tablet reduces the amount of acid your stomach makes and relieves the pain associated with heartburn and acid reflux. You should take it exactly as it is prescribed for it to be effective. Some simple lifestyle changes can help reduce the symptoms of GERD. Think about what foods trigger heartburn and try to avoid them; eat smaller, more frequent meals; try to lose weight if you are overweight and try to find ways to relax. Do not eat within 3-4 hours of going to bed.
Syspride Mps 125mg/10mg Tablet may cause excessive drowsiness with alcohol.
Syspride Mps 125mg/10mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Information regarding the use of Syspride Mps 125mg/10mg Tablet during breastfeeding is not available. Please consult your doctor.
It is not known whether Syspride Mps 125mg/10mg Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Syspride Mps 125mg/10mg Tablet is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor.
Syspride Mps 125mg/10mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Syspride Mps 125mg/10mg Tablet may be needed. Please consult your doctor.
If you miss a dose of Syspride Mps 125mg/10mg Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More